20
2022
-
09
The Chinese Academy of Sciences found that NAD+ and NMN may be able to treat COVID-19
As we all know, patients with severe COVID-19 suffer from severe respiratory distress, and many people lose their lives as a result, it is urgent to find effective ways to deal with COVID-19. Although a vaccine with high protective efficacy has been developed, the rapid mutation of COVID-19 has created great uncertainty in the COVID-19 pandemic, which has made the development of COVID-19 treatment a priority option.
COVID-19 has spread rapidly around the world and has killed more than 6 million people.
As we all know, patients with severe COVID-19 suffer from severe respiratory distress, and many people lose their lives as a result, it is urgent to find effective ways to deal with COVID-19. Although a vaccine with high protective efficacy has been developed, the rapid mutation of COVID-19 has created great uncertainty in the COVID-19 pandemic, which has made the development of COVID-19 treatment a priority option.
On April 29, 2022, Zhiheng Xu (CAS), Chengfeng Qin (Beijing Institute of Microbiology and Epidemiology) and Zeping Hu (Tsinghua University) published a paper in the journal Cell Discovery entitled: Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models.
In this study, researchers found that COVID-19 infection caused genetic dysregulation in mice, and that these dysregulation were associated with NAD+ metabolism, immune responses, and cell death, which closely resembled the symptoms of COVID-19 patients.
The importance and benefits of NAD+ and NADH in humans have been generally demonstrated in numerous literatures. They are essential coenzymes in various cellular energy metabolism pathways, such as the TCA cycle and oxidative phosphorylation, which regulate metabolism and direct energy generation, respectively. They are also involved in many important biological processes, such as cell survival, aging, and inflammation. Its significance to human beings needs no further elaboration. This is also the reason why Bangtai Biological has been committed to developing NMN products since its inception.
Last year, Pang et al. found that NAD+ supplementation effectively alleviated cell death and inhibited microglial activation in the brains of mice infected with Zika virus (ZIKV). Therefore, the researchers built on this finding to investigate the therapeutic effect of NAD+ and its intermediate NMN on COVID-19.
With treatment, first, the researchers found a significant improvement in the pneumonia phenotype, including excessive inflammatory cell infiltration, hemolysis, and embolism in the lungs of COVID-19 infection
Second, the researchers found that supplementation with NAD+ and NMN significantly inhibited cell death. More strikingly, NMN supplementation averted death in 30% of older mice infected with lethal doses of COVID-19.
Finally, mechanistically, the researchers found that supplementation with NAD+ or NMN partially saved the lives of mice with gene expression and metabolic disorders caused by COVID-19 infection.
Overall, the researchers' in vivo mouse studies support trials of targeting the NAD+ pathway to treat patients with COVID-19. Trials should consider NAD+ and its intermediate NMN for the treatment of patients with COVID-19.
Related News
Pannacean (Henan) Medicine Science Technologies, Ltd.
Address: Henan Pilot Free Trade Zone Zhengzhou Area (Jingkai) Hanghai Road Jingkai 2nd Street Hanghai East Road No. 1291
Pannacean (Henan) Medicine Science Technologies, Ltd.
Address: Henan Pilot Free Trade Zone Zhengzhou Area (Jingkai) Hanghai Road Jingkai 2nd Street Hanghai East Road No. 1291
Mail：haifeng.zhang@pannacean.com
Tel:0371-55159968